Market Overview

Needham Downgrades Esperion Therapeutics to Strong Buy

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for ESPR

DateFirmActionFromTo
Jun 2017Deutsche BankInitiates Coverage OnBuy
Mar 2017NeedhamMaintainsStrong BuyStrong Buy
Mar 2017Credit SuisseUpgradesUnderperformNeutral

View More Analyst Ratings for ESPR
View the Latest Analyst Ratings

Posted-In: News Downgrades Analyst Ratings

 

Related Articles (ESPR)